SCHEMBL4512727

SCHEMBL4512727

CC(CN1CCCCC1)Oc1ccc(I)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.62
SIGMAR1 Q99720 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.48
DRD2 P14416 1/20 0.48
DRD3 P35462 1/20 0.48
ATM Q13315 1/20 0.47
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
HTT P42858 1/20 0.46
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.45
ALOX15 P16050 1/20 0.45
MCHR1 Q99705 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6838671 0.80 LTA4H (0.62) LTA4HSIGMAR1L3MBTL1POLBDRD2
SCHEMBL7140105 0.79 LTA4H (0.97) LTA4HSIGMAR1POLBCYP2D6SMN1; SMN2
SCHEMBL7139511 0.79 LTA4H (0.97) LTA4HSIGMAR1POLBCYP2D6SMN1; SMN2
SCHEMBL6835764 0.79 L3MBTL1 (0.57) LTA4HSIGMAR1L3MBTL1POLBDRD2
SCHEMBL6838647 0.78 L3MBTL1 (0.63) LTA4HL3MBTL1POLBDRD2DRD3
SCHEMBL6183042 0.77 LTA4H (0.58) LTA4HSIGMAR1L3MBTL1POLBDRD2
SCHEMBL6183131 0.76 LTA4H (0.57) LTA4HSIGMAR1POLBDRD2DRD3
Bromide SCHEMBL20604463 0.76 LTA4H (0.41) LTA4HL3MBTL1POLBATMCYP2D6
SCHEMBL11719874 0.76 LTA4H (0.53) LTA4HSIGMAR1L3MBTL1POLBDRD2
SCHEMBL256374 0.75 ACACB (0.40) LTA4HCYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618132-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-12-31 US disclosed
EP-1558578-B1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2013-03-13 EP disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 LTA4H 2076/4885SIGMAR1 156/4885L3MBTL1 1265/4885
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, NPY1R LTA4H 2552/4885SIGMAR1 107/4885L3MBTL1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.